The economic trajectory for advanced oncology diagnostics suggests a decade of rapid expansion and technological maturation. According to the latest Clinical Oncology NG market forecast, the global industry is projected to reach USD 3.13 billion by 2034, growing at an impressive CAGR of 17.3%. This growth is underpinned by the falling cost of sequencing and the expansion of reimbursement policies for NGS-based tests in major healthcare markets. As the "price per gigabase" of data continues to drop, whole-exome and even whole-genome sequencing are becoming economically viable for routine clinical use, particularly in complex or rare cancer cases where targeted panels might miss critical variants.

In the coming years, the market will likely be dominated by "Pan-Cancer" panels that screen for actionable mutations across all solid tumor types. The forecast also highlights the role of artificial intelligence in data interpretation—a current bottleneck in the NGS workflow. AI-driven bioinformatics platforms are expected to become the highest-growth sub-segment, as they enable labs to process vast amounts of raw data into actionable clinical reports in a fraction of the time. This "digitization of oncology" is expected to decentralize testing, allowing regional hospitals to offer high-level genomic insights that were previously only available at major academic centers.